18889881171
Kalkine 0
countryflagUS

Aurinia Pharmaceuticals Inc

Healthcare US AUPH

8.25USD
0.16(1.98%)

Last update at 2025-06-12T18:57:00Z

Day Range

8.108.31
LowHigh

52 Week Range

4.7110.67
LowHigh

Fundamentals

  • Previous Close 8.09
  • Market Cap1307.22M
  • Volume472823
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.49M
  • Revenue TTM220.36M
  • Revenue Per Share TTM1.54
  • Gross Profit TTM 83.38M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -106.35200M -180.20600M -102.77400M -123.70200M -64.04700M
Minority interest - - - - -
Net income -108.18000M -180.96600M -102.68000M -123.84600M -64.12000M
Selling general administrative 196.37M 171.44M 95.98M 22.15M 13.67M
Selling and marketing expenses - - - - -
Gross profit 128.37M 44.51M -0.20900M -52.54800M -40.91900M
Reconciled depreciation 2.71M 2.76M 1.37M 1.55M 1.56M
Ebit -114.17600M -180.73500M -104.29000M -82.53900M -46.20400M
Ebitda -111.47000M -178.63700M -96.19200M -80.99100M -44.63900M
Depreciation and amortization 2.71M 2.10M 8.10M 1.55M 1.56M
Non operating income net other - 0.53M 1.52M - -
Operating income -111.47000M -180.73500M -104.29000M -82.53900M -56.15800M
Other operating expenses 245.50M 226.34M 147.60M 76.57M 56.62M
Interest expense 5.12M 0.53M 5.29M 0.04M 2.23M
Tax provision 1.83M 0.76M -0.09400M 0.14M 0.07M
Interest income 5.12M 0.53M 1.52M 2.70M 2.23M
Net interest income 5.12M 0.53M 1.52M 2.66M 2.23M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.83M 0.76M -0.09400M 0.14M 0.07M
Total revenue 134.03M 45.60M 50.12M 0.32M 0.46M
Total operating expenses 239.84M 225.25M 147.60M 76.57M 56.62M
Cost of revenue 5.66M 1.09M 50.33M 52.87M 41.38M
Total other income expense net 5.12M 0.53M 1.52M -41.16300M -7.88900M
Discontinued operations - - - - -
Net income from continuing ops -108.18000M -180.96600M -102.68000M -123.84600M -64.12000M
Net income applicable to common shares -108.18000M -180.96600M -102.68000M -88.38500M -53.07900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 548.06M 470.86M 543.37M 463.66M 326.68M
Intangible assets 4.98M 6.42M 8.40M 9.33M 11.24M
Earning assets - - - - -
Other current assets 10.52M 1.33M 0.80M 6.15M 8.75M
Total liab 170.11M 65.42M 64.28M 55.91M 53.17M
Total stockholder equity 377.95M 405.44M 479.09M 407.75M 273.52M
Deferred long term liab - - - - -
Other current liab 52.45M 38.94M 4.64M 7.20M 0.12M
Common stock 1200.22M 1185.31M 1177.05M 944.33M 790.47M
Capital stock 1200.22M 1185.31M 1177.05M 944.33M 790.47M
Retained earnings -942.32200M -864.30200M -756.12200M -575.15600M -539.80600M
Other liab - 12.17M 15.95M 16.30M 14.41M
Good will - - - - -
Other assets - 13.34M 11.84M 5.74M 0.21M
Cash 48.88M 94.17M 231.90M 272.35M 306.02M
Cash and equivalents - - - - -
Total current liabilities 77.19M 46.11M 40.65M 32.00M 11.29M
Current deferred revenue 4.81M 3.15M 31.07M 21.37M 0.12M
Net debt 48.73M -86.08400M -223.16100M -263.94300M -306.01900M
Short term debt 15.60M 0.94M 1.06M 0.79M 6.91M
Short long term debt - - - - -
Short long term debt total 97.61M 8.09M 8.74M 8.41M -
Other stockholder equity 120.79M 85.49M 59.01M 39.38M 23.66M
Property plant equipment - 8.56M 9.80M 4.79M 0.09M
Total current assets 424.80M 442.54M 513.32M 419.43M 315.14M
Long term investments 0.20M - 0.00000M 24.38M -
Net tangible assets - 399.01M 470.69M 398.42M 289.74M
Short term investments 301.61M 295.22M 234.18M 125.98M 0.00000M
Net receivables 24.09M 13.48M 15.41M 1.02M 0.37M
Long term debt - - - - -
Inventory 39.70M 24.75M 19.33M 13.93M -
Accounts payable 4.33M 3.09M 3.88M 2.63M 4.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.73000M -1.06100M -0.85200M -0.80500M -0.80500M
Additional paid in capital - - - - -
Common stock total equity - - 1177.05M 944.33M 790.47M
Preferred stock total equity - - - - -
Retained earnings total equity - - -756.12200M -575.15600M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.52M 13.34M 11.84M 0.25M 0.21M
Deferred long term asset charges - - - - -
Non current assets total 123.26M 28.32M 30.04M 44.23M 11.55M
Capital lease obligations 97.61M 8.09M 8.74M 8.41M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -60.63200M -84.53100M -150.84300M 7.78M -0.06600M
Change to liabilities 3.75M 4.08M 13.62M 4.01M -0.88700M
Total cashflows from investing activities -60.63200M -103.87000M -158.18600M 7.78M -0.06500M
Net borrowings - - - -0.12700M -0.12700M
Total cash from financing activities 2.43M 221.11M 194.38M 243.73M 4.01M
Change to operating activities -3.41900M -4.65000M 4.83M -1.97700M -5.11200M
Net income -108.18000M -180.96600M -102.68000M -123.84600M -64.12000M
Change in cash -137.72800M -40.45000M -33.66900M 188.05M -47.66200M
Begin period cash flow 231.90M 272.35M 306.02M 117.97M 165.63M
End period cash flow 94.17M 231.90M 272.35M 306.02M 117.97M
Total cash from operating activities -79.52900M -157.69200M -69.85800M -63.45600M -51.61000M
Issuance of capital stock 0.00000M 196.74M 187.73M 223.12M -
Depreciation 2.71M 2.76M 1.37M 1.55M 1.56M
Other cashflows from investing activities -0.66300M -11.83800M -7.34300M -1.67500M -1.67500M
Dividends paid - - - - -
Change to inventory -9.07200M -5.64400M -13.92700M -13.92700M -13.92700M
Change to account receivables 1.93M -15.41500M -13.62000M -0.15100M -0.10800M
Sale purchase of stock - 221.11M 194.38M 243.85M 4.01M
Other cashflows from financing activities -60.63200M 24.37M 6.64M 20.74M 4.01M
Change to netincome 32.76M 42.15M 20.13M 21.60M 6.15M
Capital expenditures 0.29M 1.50M 7.34M 0.10M 0.07M
Change receivables - -15.41500M -0.65000M - -
Cash flows other operating - 5.35M 12.28M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -40.45000M -33.66900M - -
Change in working capital -6.81700M -21.63300M 4.52M 2.13M -6.00000M
Stock based compensation 32.30M 31.24M 17.45M 7.41M 6.86M
Other non cash items 0.46M 10.90M 9.48M 8.15M 0.12M
Free cash flow -79.82100M -159.19300M -77.20100M -63.56000M -51.68500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AUPH
Aurinia Pharmaceuticals Inc		 0.16 1.98% 8.25 - 12.97 5.93 3.29 4.62 231.82
NVO
Novo Nordisk A/S		 2.11 2.68% 80.84 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 2.40 3.07% 80.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 6.68 1.48% 459.12 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.42 1.05% 524.02 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6

Key Executives

Name Title Year Born
Mr. Peter S. Greenleaf M.B.A. Pres, CEO & Director 1970
Mr. Joseph M. Miller CPA Chief Financial Officer 1974
Mr. Matthew Maxwell Donley M.B.A. Exec. VP of Operations & Strategy 1969
Mr. Stephen P. Robertson Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer 1982
Ms. DeDe Sheel VP of Investor Relation NA
Mr. Chris Hays VP of Marketing NA
Mr. Fran Lynch VP of Sales NA
Mr. Michael R. Martin Chief Bus. Officer 1972
Ms. Sue Evans Head of Regulatory Affairs NA
Mr. Scott Habig Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.